Human Peritoneal Cancer Organoid
Human Peritoneal Cancer Organoid is a 3D tissue model derived from human peritoneal cancer tissues, accurately replicating the structure and function of the peritoneal carcinoma microenvironment. These organoids retain the molecular characteristics and tumor heterogeneity of the original cancer, including key features such as epithelial-to-mesenchymal transition (EMT) and tumor-stroma interactions. They are valuable for studying peritoneal cancer progression, tumor biology, and chemoresistance. Human peritoneal cancer organoids serve as an ideal platform for disease modeling, drug testing, and targeted therapy development. Their use provides insights into the peritoneal tumor microenvironment, enabling more accurate prediction of patient-specific therapeutic responses. These organoids undergo rigorous testing for mycoplasma, bacteria, fungi/yeast, and are verified for identity, genetic stability, and functional performance.
Specifications
- cat no
- C-086
- disease
- Cancer
- organism
- Human
- tissue
- Peritoneum
- growth properties
- Embedded 3D Culture
- biosafety level
- 1
- growth conditions
- 37℃, 95% Air, 5% CO 2
- size quantity
- 1
- product format
- Frozen
- shipping info
- Dry Ice
- storage conditions
- Liquid Nitrogen
- quality control
- All test negative for mycoplasma, bacteria, yeast, and fungi.
- application
- For research use only. The organoid is well-suited for translational cancer research, including the study of peritoneal tumor progression, drug resistance, and personalized treatment response. It enables preclinical screening of cytotoxic agents and targeted therapies, including those used in intraperitoneal chemotherapy. Researchers can use this model to investigate tumor–stroma interactions, explore immunotherapy combinations, and validate biomarkers associated with metastasis and recurrence. The Human Peritoneal Cancer Organoid is especially useful for modeling patient-specific therapeutic outcomes, aiding in the development of precision oncology strategies for peritoneal surface malignancies.